Literature DB >> 20708576

Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers.

Denise Milovan1, Luis Almeida, Myroslava K Romach, Teresa Nunes, José Francisco Rocha, Marta Sokowloska, Edward M Sellers, Patrício Soares-da-Silva.   

Abstract

The results of two single-blind studies conducted to evaluate the cognitive and psychomotor effects of eslicarbazepine acetate and oxcarbazepine following single and repeated administration in healthy volunteers are reported. The cognitive and psychomotor evaluation consisted of several computerized and paper-and-pencil measures. Eslicarbazepine acetate and oxcarbazepine had similar overall cognitive profiles and did not cause clinically relevant cognitive impairment. The incidence of adverse events was lower with eslicarbazepine acetate than with oxcarbazepine. Copyright 2010. Published by Elsevier Inc.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20708576     DOI： 10.1016/j.yebeh.2010.04.022

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN： 1525-5050            Impact factor:   2.937


  10 in total

Review 1.  Cognitive and fatigue side effects of anti-epileptic drugs: an analysis of phase III add-on trials.

Authors:  Rani A Sarkis; Yazel Goksen; Yi Mu; Bernard Rosner; Jong Woo Lee
Journal:  J Neurol       Date:  2018-07-12       Impact factor: 4.849

Review 2.  Novel medications for epilepsy.

Authors:  Cinzia Fattore; Emilio Perucca
Journal:  Drugs       Date:  2011-11-12       Impact factor: 9.546

Review 3.  The Challenge of Pharmacotherapy in Children and Adolescents with Epilepsy-ADHD Comorbidity.

Authors:  Alberto Verrotti; Romina Moavero; Gianvito Panzarino; Claudia Di Paolantonio; Renata Rizzo; Paolo Curatolo
Journal:  Clin Drug Investig       Date:  2018-01       Impact factor: 2.859

4.  Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users.

Authors:  Hans G Cruz; Petra Hoever; Bijan Chakraborty; Kerri Schoedel; Edward M Sellers; Jasper Dingemanse
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

Review 5.  Eslicarbazepine acetate: a review of its use as adjunctive therapy in refractory partial-onset seizures.

Authors:  Gillian M Keating
Journal:  CNS Drugs       Date:  2014-07       Impact factor: 5.749

6.  [Slow release versus immediate release oxcarbazepine in difficult-to-treat focal epilepsy: a multicenter, randomized, open, controlled, parallel group phase III study].

Authors:  B J Steinhoff; H Stefan; A Schulze-Bonhage; R Hueber; W Paulus; M Wangemann; C E Elger
Journal:  Nervenarzt       Date:  2012-10       Impact factor: 1.214

7.  Update on treatment of partial onset epilepsy: role of eslicarbazepine.

Authors:  Markus Rauchenzauner; Gerhard Luef
Journal:  Neuropsychiatr Dis Treat       Date:  2010-11-02       Impact factor: 2.570

8.  A study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphan/quinidine and memantine in healthy volunteers.

Authors:  Laura E Pope; Kerri A Schoedel; Cynthia Bartlett; Edward M Sellers
Journal:  Clin Drug Investig       Date:  2012-08-01       Impact factor: 2.859

Review 9.  Eslicarbazepine acetate in the treatment of adults with partial-onset epilepsy: an evidence-based review of efficacy, safety and place in therapy.

Authors:  Simona Lattanzi; Francesco Brigo; Claudia Cagnetti; Alberto Verrotti; Gaetano Zaccara; Mauro Silvestrini
Journal:  Core Evid       Date:  2018-03-08

10.  Alterations in Neural Networks During Working Memory Encoding Related to Cognitive Impairment in Temporal Lobe Epilepsy.

Authors:  Liping Pan; Yakun Wu; Jie Bao; Dandan Guo; Xin Zhang; Jiajing Wang; Meili Deng; Peiran Yu; Gaoxu Wei; Lulin Zhang; Xiao Qin; Yijun Song
Journal:  Front Hum Neurosci       Date:  2022-01-05       Impact factor: 3.169
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.